A NEURO-BIO PAPER ACCEPTED

NEWS

Modulatory Effects of a Novel Cyclized Peptide in Reducing the Expression of Markers Linked to Alzheimer's Disease by Emanele Brai, Florian Simon, Antonella Cogoni and Susan A. Greenfield

Despite many studies attempt to identify the primary mechanisms underlying neurodegeneration in 10 Alzheimer’s disease (AD), the key events still remain elusive. We have previously shown that a 11 peptide cleaved from the acetylcholinesterase (AChE) C-terminus (T14) can play a pivotal role as a 12 signaling molecule in neurodegeneration, via its interaction with the α7 nicotinic acetylcholine 13 receptor.

The main goal of this study is to determine whether a cyclized variant (NBP14) of the toxic 14 AChE-derived peptide can antagonize the effects triggered by the linear fragment in modulating well-15 known markers linked to neurodegeneration. We investigate this hypothesis applying NBP14 on ex-16 vivo rat brain slices containing the basal forebrain. Western blot analysis revealed an inhibitory action 17 of NBP14 on naturally occurring T14 peptide, as well as on endogenous amyloid beta, whereas the 18 expression of the nicotinic receptor and phosphorylated Tau was relatively unaffected. These results 19 further confirm the neurotoxic properties of the AChE-peptide and show for the first time in an ex-20 vivo preparation the apparent neuroprotective activity of NBP14, over a protracted period of hours, 21 indicating that T14 pathway may offer a new prospect for therapeutic intervention in AD 22 pathobiology.

To read the full paper please Click here